You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Article metrics

Article menu
XML
Oncolytic and local immunotherapy
Original research
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

 

Online download statistics by month:

Online download statistics by month: July 2021 to February 2026

AbstractFullPdf
Jul 2021310310120
Aug 202119419575
Sep 202112112160
Oct 202116616639
Nov 202111311233
Dec 202110710724
Jan 2022677030
Feb 2022545532
Mar 2022848733
Apr 2022919643
May 2022919124
Jun 2022727742
Jul 202213213339
Aug 202210610844
Sep 2022828457
Oct 2022576330
Nov 2022525234
Dec 2022484816
Jan 2023505014
Feb 202310410432
Mar 202310110341
Apr 2023515117
May 2023626236
Jun 2023555721
Jul 2023484825
Aug 2023515120
Sep 2023414116
Oct 2023434320
Nov 2023646417
Dec 2023717131
Jan 2024585926
Feb 2024383923
Mar 2024656741
Apr 2024656753
May 2024586124
Jun 2024788034
Jul 202410610725
Aug 2024656424
Sep 2024697031
Oct 2024717137
Nov 2024888955
Dec 2024818226
Jan 2025687053
Feb 2025636335
Mar 2025646433
Apr 2025727523
May 2025707048
Jun 2025404125
Jul 2025110
Aug 2025110
Sep 2025330
Feb 2026110
Total391339651681